A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer

NCT07253142 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer
Small Cell Lung Cancer

Interventions

DRUG: HLX43 dose 1
DRUG: HLX43 dose 2

Sponsor

Shanghai Henlius Biotech